Company: SCLXW
Filing Date: 2025-05-14
Form Type: 424B3
Source: 0001193125-25-119831
Chunk: 25

Company: Scilex Holding Co
Filing Date: 2025-05-14
Form: 424B3
Chunk 25
---
 Licensee’s sale of the Gloperba Products, and the Licensee shall effect the foregoing by paying to us an amount required for us to receive its share of the Net Revenue on
a quarterly basis.

Pursuant to the Gloperba License Agreement, the Licensee shall obtain and maintain regulatory approval for the
Gloperba Product outside of the United States in accordance with its own business judgment and in its sole and absolute discretion.

Promptly after the Effective Date, we are required to (i) facilitate an introduction between the Licensee and our contract manufacturer
of the Gloperba Product (the “Gloperba CMO”) as of the Effective Date, and (ii) use reasonable efforts to cause such Gloperba CMO to accept a direct engagement with the Licensee for the manufacturing or supply of the Gloperba Product
in finished dosage form. In addition, we agreed to appoint the Licensee as its exclusive distributor of the Gloperba Product in the entire world other than the United States during the Gloperba License Term.

The term of the Gloperba License Agreement commences on the Effective Date and continues until expiration of the last to expire Licensed
Patents (as defined therein), unless earlier terminated (the “Gloperba License Term”).

Bid Price Deficiency & Reverse Split

On November 1, 2024, we received a letter (the “Notice”) from Nasdaq notifying the Company that, because the
closing bid price for its Common Stock has been below $1.00 per share for 30 consecutive business days, it did not comply with the minimum bid price requirement for continued listing on The Nasdaq Capital Market. Nasdaq Listing Rule 5550(a)(2)
requires listed securities to maintain a minimum bid price of $1.00 per share (the “Minimum Bid Price Requirement”), and Nasdaq Listing Rule 5810(c)(3)(A) provides that a failure to meet the Minimum Bid Price Requirement exists if the
deficiency continues for a period of 30 consecutive business days. The Notice also indicated that the Company had 180 calendar days, or until April 30, 2025 (the “Compliance Period”), to regain compliance pursuant to Nasdaq Listing
Rule 5810(c)(3)(A).

On March 19, 2025 at a special meeting of our stockholders, our stockholders approved the amendment of our
Certificate of Incorporation to effect a reverse stock split within a range of 1-for-